Dry Eye

Alcon’s dry eye candidate acoltremon 0.003% is a first-in-class thermoreceptor agonist, which stimulates corneal sensory nerves to increase natural tear production to treat the signs and symptoms of dry eye disease.

Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, ponders about what she would like to see develop as both a researcher and a clinician in the dry eye space.

Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, discussed research that utilized IQVIA longitudinal prescription claims data from September through November 2023, coinciding with Miebo's FDA approval in September.

The study targets a prevalent yet under-addressed component of dry eye disease: lipid layer dysfunction, implicated in approximately 86% of dry eye cases, especially those associated with screen use and environmental exposure.

The drop has the potential to become the first-ever ocular surface indication for an IG.

Can a drop of perfluorohexyloctane, known to persist in the tear film, influence the precision of keratometry and ultimately affect surgical planning?

When her friend began experiencing dry eye symptoms while undergoing chemotherapy, Katherine Mastrota, OD, MS, FAAO, Dipl ABO, found herself in a unique position to provide specialized advice.

New data for 0.25% reproxalap was announced by Aldeyra Therapeutics, supporting the company’s NDA resubmission for the treatment of dry eye disease.

Participants received either Systane Hydration UD (Alcon, Fort Worth, TX) or saline eye drops (NeilMed, Santa Rosa, CA) 4 times a day for 4 weeks each.

Elise Kramer, OD, FAAO, FSLS, describes how she uses myriad tools to help her patients with dry eye manage the condition, especially in conjunction with contact lenses.

Inflammation is both a cause and consequence of dry eye disease.

Deborah Ristvedt, DO, and Melissa Tawa, OD, FAAO, detail the benefits of interventional glaucoma during their CRU 2025 presentation.

Under the Vevye Access for All program, patients with a Klarity-C prescription can switch to Vevye for $59 per bottle.

Cecelia Koetting, OD, FAAO, DipABO, and Madeline Yung, MD, detailed the prevalence of the conditions, diagnostic tools, and treatment options.

Nordic Pharma plans to announce commercialization details in the near future for the dry eye disease treatment.

Healing properties can accelerate and improve outcomes for patients.

The company stated that the FDA noted at least one additional adequate and well controlled study to demonstrate a positive effect on the treatment of ocular symptoms of dry eye should be conducted.

Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.

Lab TRIACTIV is powered by “advanced cationic liposomal technology” for dry eye relief and targets all 3 layers of the tear film.

An overview of prescription medications available for DED.

Patients reported that Miebo significantly reduced overall symptoms severity at the primary endpoint of change from baseline in the severity of overall dry eye symptoms at day 7.

VEVYE Access for All aims to reduce barriers to dry eye disease therapy via a partnership with PhilRx.

Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO; Brianna Rhue, OD, FAAO, FSLS; Ben Casella, OD; and Ben Gaddie, OD, FAAO shared their insights from the conference.